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Androgen deprivation therapy (ADT) is widely used in the
management of prostate cancer at essentially all stages and
presentations. For example, in addition to its obvious key role
in the management of metastatic disease, ADT is commonly
used in combination with external beam radiation therapy
(EBRT) for high risk or locally advanced disease for dura-
tions of 6 months to 3 years. In this scenario several large
mature multi-institution randomized trials have shown a sur-
vival beneﬁt.1–3 For intermediate risk disease the addition of
ADT to conventional dose radiotherapy (65–70Gy) improves
both biochemical disease free survival and overall survival.4
However, in both intermediate and high risk disease, the
role of ADT is being challenged and is beginning to decrease
in importance as the ability to deliver very high biologically
effective doses (BED) becomes more widely available, espe-
cially though the combination of external radiotherapy and
brachytherapy. Brachytherapy as a form of dose escalation,
either low dose rate or high dose rate, achieves biologically
effective doses much higher than can be achieved with EBRT,
dramatically changing the pattern of failure.5 Local recurren-
ces are markedly reduced, eliminating the second wave of
distant metastatic failures that emanate from uncontrolled
local tumor and improving disease speciﬁc mortality.
The side effects of ADT are well documented and include
not only sexual dysfunction, loss of libido and hot ﬂashes,
but also osteoporosis, obesity, insulin resistance and diabetes,
alterations in lipids, cardiovascular disease, fatigue, decreased
muscle mass, depression, and even cognitive dysfunction.6
The metabolic syndrome, characterized by central obesity,
elevated triglycerides, reduced high-density lipoproteins, ele-
vated blood pressure and elevated fasting glucose is present
in over 50% ofmen undergoing long-termADT as compared to
22% of prostate cancer patients not receiving ADT. However,
despite these common and occasionally serious side effects,
ADT is frequently used in situations where evidence of ben-
eﬁt is lacking, such as combined with deﬁnitive radiotherapy
for favorable risk prostate cancer,7 or in the case of primary
management of the elderly patient with low risk disease.8
Large randomized trials have demonstrated not only lack of
beneﬁt but possible harm in these situations.
When ADT is indicated, patients should be informed of
the potential side effects and encouraged to correct life
style related co-morbidities by stopping smoking, adopting
a healthy diet and commencing a regular exercise program.
Their BodyMass Index should be recorded and blood pressure,
blood sugar and serum lipids should be optimized. If there is a
history of cardiovascular disease, assessment by a cardiologist
is appropriate.
For biochemically recurrent disease after deﬁnitive therapy,
a Canadian-lead international trial (NCIC PR7) has demon-
strated that an intermittent approach, with 8–9 month
treatment cycles interspersed with variable length off-
treatment periods, results in the same overall survival as the
continuous ADT approach and has advantages in terms of
quality of life.9 A similar trial for newly diagnosed metastatic
disease (SWOG 9346) resulted in equivocal ﬁndings10 but some
subgroups of patients with metastatic disease, such as those
who are asymptomatic, may be considered for this approach
provided careful monitoring is undertaken.
Appropriately selecting patients for ADT according to
established indications will minimize the number exposed,
while systematic patient education prior to initiating treat-
ment can ameliorate the side effects.
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